Hints and tips:
...Banco Santander, BT Group, Centrica, CMC Markets, Co-operative Bank, CVS Group, Diageo, Enel, Hammerson, JCDecaux, L’Oréal, Leonardo, Nestlé, OMV, Orange, Relx, Rentokil Initial, Repsol, Royal Dutch Shell, Sanofi-Aventis...
...H1, Mastercard Q2, Merck & Co Q2, Nestlé H1, Nissan Motor Q1, Northrop Grumman Q2, OMV Q2, Orange H1, Panasonic Q1, Pfizer Q2, Relx H1, Rentokil Initial H1, Repsol Q2, Royal Dutch Shell Q2, Samsung Q2, Sanofi-Aventis...
...Markit construction PMI data US, monthly motor vehicle sales, payrolls and unemployment figures Results: Aon Q4, Bristol-Myers Squibb Q4, Carlsberg FY, Intesa Sanpaolo FY, Regeneron Pharmaceuticals Q4, Sanofi-Aventis...
...Q2 Mediobanca Q2 Merck & Co Q2 National Express H1 Nestle H1 Northrop Grumman Q2 Orange H1 Panasonic Q1 Pinterest Q1 Rentokil H1 Repsol Q2 Royal Dutch Shell Q2 Saint-Gobain H1 Samsung Q2 Sanofi-Aventis...
...Mr Pigasse has advised some of France’s largest companies, including Carrefour, Sanofi, L’Oréal and Danone, and carved out a reputation advising on sovereign debt restructuring for Iraq, Ecuador, Argentina...
...A joint venture agreed with Sanofi in 2016 is aimed at improving diabetes care. These moves might not pay off....
...for Just Eat to £5bn as it seeks to clinch deal (FT) Former Guggenheim Partners president made bid for Premier League’s Chelsea (WSJ) IFF vies with Kerry in deal for DuPont nutrition business (BBG) Sanofi...
...Verily products like Onduo, a joint venture with Sanofi to create a diabetes management platform, might move closer to Google Health....
...Large corporations, including Unilever, Akzo Nobel and Sanofi, are all looking to dispose of multibillion units in the coming months and are all likely targets for private equity....
...For instance, Sanofi’s anti-clotting drug Plavix had 83 per cent of the market for drugs of its class in 2016, but that will fall to 60 per cent by 2020, as Chinese company Shenzhen Salubris makes gains,...
...We are cash rich . . . we have our Sanofi stake, we are absolutely financially very solid and we have what it takes to do anything.”...
...AkzoNobel has also put its specialty chemicals unit up for sale, and Sanofi is selling a drug unit. Both auctions have attracted interest from private equity....
...Sanofi, the French drugmaker, is seeking to sell its European generic drug business for about €3bn, drawing interest from a consortium formed by Cinven and Bain Capital....
...Last month, Sanofi the French pharmaceutical company said it would buy Bioverativ, a US biotech group focused on haemophilia treatments, for $11.6bn — a premium of about 64 per cent to where it was trading...
...After a spate of foreign takeovers of Indian drugmakers by companies such as Daiichi Sankyo, Sanofi-Aventis and Abbott Laboratories in the past decade, some policymakers demanded that pharmaceuticals be...
...It could add another €10bn by selling its stake in drugmaker Sanofi. Buying and cancelling the shares would add about 15 per cent to L’Oréal’s earnings per share, thinks RBC....
...Mr Miels started his pharmaceuticals career at AstraZeneca in 1995, leaving in 2000 for Sanofi-Aventis before joining Switzerland’s Roche in 2006, where he ran the company’s Asia business....
...While not seen in Germany before, Braas’s tactic has some similarities to that deployed by French drugmaker Aventis in 2004, in an attempt to avoid being acquired by Sanofi in a $60bn deal....
...I am delighted to welcome Yong-Jun to the Sanofi family....
...Since last Thursday more than $55bn have been spent by large companies, including Abbott Laboratories, AbbVie and Sanofi to secure growth generating assets....
...Sanofi and Aventis merged to take on US pharma, but have not caught Pfizer. Nor have Glaxo and SmithKline Beecham....
...One of the latest signs of progress came in April 2016 when the World Health Organisation recommended that countries consider using Sanofi’s vaccine to combat dengue fever....
...Later he was with Aventis, another Franco-German drugmaker, in the US when it merged with France’s Sanofi. His experience of these deals was mostly negative. “Sanofi-Aventis didn’t work,” he says....
...A full auction has begun with GlaxoSmithKline, Sanofi and Galenica of Switzerland among the potential bidders, the people said....
...In Bayer’s case, the shift to life sciences started as long ago as 2001, when the group paid €7.25bn for Aventis CropScience in what was then its largest acquisition....
International Edition